Paper Details

  1. Home
  2. Paper Details

Profile of leukocyte-endothelial cell interactions induced in venules and arterioles by nucleoside reverse-transcriptase inhibitors in vivo.

Author: AlvarezAngeles, BarrachinaMaría D, De PabloCarmen, EspluguesJuan V, OrdenSamuel, PerisJose E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Abacavir and didanosine, two nucleoside reverse-transcriptase inhibitors used to treat human immunodeficiency virus (HIV) infection, increased leukocyte-endothelium interactions in rat and human cells, suggesting a potential association with cardiovascular (CV) diseases.
Paper Details　
Original Abstract of the Article :
BACKGROUND: There is controversy regarding cardiovascular (CV) toxicity of the nucleoside reverse-transcriptase inhibitors used to treat human immunodeficiency virus infection. METHODS: We evaluated the effects of nucleoside reverse-transcriptase inhibitors on leukocyte-endothelium interactions, a ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/jit340

データ提供：米国国立医学図書館（NLM）

Exploring the Cardiovascular Side Effects of Nucleoside Reverse-Transcriptase Inhibitors

This study ventures into the complex landscape of cardiovascular (CV) health, specifically focusing on the potential effects of nucleoside reverse-transcriptase inhibitors (NRTIs), a class of drugs used to treat HIV infection. NRTIs are a cornerstone of HIV treatment, but there has been controversy regarding their potential cardiovascular toxicity. This study aims to shed light on the effects of NRTIs on leukocyte-endothelial interactions, a crucial component of CV health.

The Cardiovascular Impact of NRTIs: A Closer Look

The research found that abacavir and didanosine, two specific NRTIs, significantly increased leukocyte-endothelial interactions in both rat and human cells. These interactions are known to play a crucial role in the development of cardiovascular diseases. The study's findings provide further evidence linking abacavir and didanosine with increased risk of cardiovascular complications in HIV patients.

Navigating the Cardiovascular Risks of HIV Treatment

This study emphasizes the importance of monitoring cardiovascular health in HIV patients undergoing treatment with NRTIs. Healthcare professionals should be aware of the potential cardiovascular risks associated with specific NRTIs, such as abacavir and didanosine, and take appropriate steps to manage these risks. The study's findings highlight the need for a careful balance between HIV treatment and cardiovascular health management.

Dr.Camel's Conclusion

This study underscores the complex interplay between HIV treatment and cardiovascular health. While NRTIs are essential for controlling HIV infection, certain NRTIs can increase the risk of cardiovascular complications. The study's findings highlight the importance of individualized treatment plans that consider both HIV control and cardiovascular health management.

Date :
  1. Date Completed 2013-11-22
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

23908487

DOI: Digital Object Identifier

10.1093/infdis/jit340

Related Literature

Article Analysis
・Effects of lamivudine and zidovudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.